Cat. #152707
A2780ADR Cell Line
Cat. #: 152707
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 10-12 weeks
Organism: Human
Tissue: Ovary
Disease: Cancer
Model: Tumour line
£800.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Timothy Ward
Institute: National Cancer Institute
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: A2780ADR Cell Line
- Alternate name: A2780 ADR; A2780/ADR; A2780-ADR; A2780Adr; A2780ADR Cells; adriamycin-resistant cell line
- Cancer: Carcinoma
- Cancers detailed: Carcinoma
- Research fields: Cancer;Drug development
- Tool sub type: Continuous
- Parental cell: A2780
- Organism: Human
- Tissue: Ovary
- Disease: Cancer
- Growth properties: Adherent
- Model: Tumour line
- Conditional: Yes
- Description: Access an adriamycin-resistant derivative of the gold standard ovarian cancer line A2780. The A2780 series of ovarian cancer cell lines have been effective cancer research tools for over 20 years. A2780ADR is an adriamycin-resistant cell line that has been developed by exposure of adriamycin to the parent A2780 cell line (catalogue no. 152706). Adriamycin (doxorubicin) is frequently used as a therapeutic agent for cancer, by interfering with DNA replication. A2780ADR cells grow as a monolayer and in suspension in spinner cultures and are tumourigenic in immune deficient mice. To maintain resistance, adriamycin must be added to the culture medium. Key features of A2780ADR: (1) Cross-resistance to melphalan and vinblastine. (2) Useful in investigation of drug resistance mechanisms in cancer.
- Application: Study of drug transport, toxicity testing, drug resistance cancer studies
- Production details: Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 5x1,000 to 2x10,000 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. Recommendation: culture cells without drug after resuscitation until growth has been fully established.
- Additional notes: STR-PCR Data: Amelogenin: X CSF1PO: 10,11 D13S317: 13 D16S539: 11,14 D5S818: 11,12 D7S820: 10 THO1: 6 TPOX: 8,9 vWA: 15,16
- Cellosaurus id: CVCL_1941
Target Details
- Target: Adriamycin resistance
Applications
- Application: Study of drug transport, toxicity testing, drug resistance cancer studies
- Application notes: STR-PCR Data: Amelogenin: X CSF1PO: 10,11 D13S317: 13 D16S539: 11,14 D5S818: 11,12 D7S820: 10 THO1: 6 TPOX: 8,9 vWA: 15,16
Handling
- Format: Frozen
- Growth medium: RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS); treatment with 10E-7 M adriamycin at least once a week.
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Subculture routine: Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4 x10,000cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C.
Related Tools
- Related tools: A2780 Cell Line ; A2780cis Cell Line
References
- Miller et al. RSC Adv. 2018. 8(69):39731-39734. PMID: 30713687.
- Singh et al. Int J Pharm. 2015. 478(2):745-752. PMID: 25437111.
- Beaufort et al. 2014. PLoS One. 9(9):e103988. PMID: 25230021.
- Hamilton et al. 1984. Semin Oncol. 11(3):285-298. PMID: 6385258.
